サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1534251

泌尿生殖器治療薬の世界市場調査レポート：産業分析、規模、シェア、成長、動向、予測（2024年～2032年）

Global Genitourinary Drugs Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032
出版日: | 発行: Value Market Research | ページ情報: 英文 130 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=149.25円
泌尿生殖器治療薬の世界市場調査レポート：産業分析、規模、シェア、成長、動向、予測（2024年～2032年）
出版日: 2024年07月01日
発行: Value Market Research
ページ情報: 英文 130 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の泌尿生殖器治療薬の市場規模は、2023年の352億3,000万米ドルから、2032年には412億2,000万米ドル近くに達し、調査期間2024年～2032年のCAGRは1.76%と推定されます。

泌尿生殖器治療薬は、泌尿器や生殖器に影響を及ぼす疾患や疾病を治療するために設計された医薬品です。これらの医薬品には、抗生物質、抗ウイルス剤、抗真菌剤、ホルモン剤、免疫抑制剤など、さまざまな治療カテゴリーが含まれます。これらの薬剤は、尿路感染症（UTI）、勃起不全、前立腺肥大症（BPH）、不妊症、性感染症（STI）、泌尿生殖器系の各種がんなどの症状の管理に使用されます。治療対象の疾患や障害に応じて、これらの薬剤は病原体を標的にしたり、ホルモンレベルを調節したり、炎症を抑えたり、がん細胞の増殖を抑制したりします。

市場力学

泌尿生殖器治療薬市場は、泌尿生殖器系疾患の有病率の増加、治療薬開発の進展、進化する医療人口動態によって牽引されています。尿路結石、前立腺疾患、性感染症などの泌尿生殖器疾患の罹患率が上昇していることが、効果的な医薬品治療に対する需要を促進しています。急速な都市化、ライフスタイルの変化、人口の高齢化が疾病負担の増加に寄与しており、泌尿生殖器治療薬の継続的な技術革新が必要とされています。さらに、ドラッグデリバリーシステム、個別化医療アプローチ、バイオマーカー同定の進歩は、治療効果と患者の転帰を向上させます。前立腺がんや勃起不全のような疾患に対する標的治療は、治療の選択肢を広げ、罹患者の生活の質を向上させています。さらに、医療支出の増加と泌尿器科研究への投資が市場拡大の原動力となっています。製薬会社は、泌尿器科医療におけるアンメット・メディカル・ニーズに対応するため、新規治療薬の開発と既存薬の適応拡大に注力しています。生殖に関する健康意識の高まり、積極的なスクリーニングの取り組み、患者教育プログラムも泌尿生殖器治療薬市場の成長を促進します。医療提供者や政策立案者は予防医療や早期介入戦略を優先しており、泌尿生殖器治療薬の市場浸透を支えています。しかし、医薬品承認や特許失効に関する厳しい規制要件が市場成長の課題となっています。

本調査レポートでは、ポーターのファイブフォースモデル、市場の魅力分析、バリューチェーン分析を取り上げています。これらのツールは、業界の構造を明確に把握し、世界レベルでの競合の魅力を評価するのに役立ちます。さらに、これらのツールは、泌尿生殖器治療薬の世界市場における各セグメントを包括的に評価することもできます。泌尿生殖器治療薬業界の成長と動向は、この調査への全体的なアプローチを提供します。

市場セグメンテーション

本セクションでは、泌尿生殖器治療薬市場の国別・地域別セグメントに関する詳細なデータを提供し、戦略担当者が各製品・サービスのターゲット層を特定する上で、今後のビジネスチャンスをサポートします。

地域分析

本セクションでは、北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカの地域展望をカバーし、泌尿生殖器治療薬市場の現在と将来の需要を明らかにしています。さらに、すべての主要地域における個々の用途セグメントの需要・推定・予測にも焦点を当てています。

カスタム要件がある場合は、お問い合わせください。当社の調査チームは、お客様のニーズに応じてカスタマイズしたレポートを提供することができます。

目次

第1章 序文

第2章 エグゼクティブサマリー

  • 市場のハイライト
  • 世界市場スナップショット

第3章 泌尿生殖器治療薬-産業分析

  • イントロダクション：市場力学
  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 業界動向
  • ポーターのファイブフォース分析
  • 市場の魅力分析

第4章 バリューチェーン分析

  • バリューチェーン分析
  • 原材料分析
    • 原材料リスト
    • 原材料メーカーリスト
    • 主要原材料の価格動向
  • 潜在的バイヤーのリスト
  • マーケティングチャネル
    • ダイレクトマーケティング
    • インダイレクトマーケティング
    • マーケティングチャネル発展動向

第5章 泌尿生殖器治療薬の世界市場分析：病状別

  • 病状別の概要
  • 病状別の実績・予測データ分析
  • 前立腺がん
  • 卵巣がん
  • 膀胱がん
  • 子宮頸がん
  • 腎臓がん
  • 勃起不全
  • 尿路感染症
  • 尿失禁と過活動膀胱
  • 性感染症
  • 間質性膀胱炎
  • 血尿
  • 前立腺肥大症

第6章 泌尿生殖器治療薬の世界市場分析：製品別

  • 製品別の概要
  • 製品別の実績・予測データ分析
  • 泌尿器科
  • ホルモン療法
  • 婦人科
  • 抗感染症薬
  • その他

第7章 泌尿生殖器治療薬の世界市場分析：地域別

  • 地域別展望
  • イントロダクション
  • 北米の売上分析
    • 概要・実績・予測
    • 北米：セグメント別
    • 北米：国別
    • 米国
    • カナダ
    • メキシコ
  • 欧州の売上分析
    • 概要・実績・予測
    • 欧州：セグメント別
    • 欧州：国別
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • ロシア
    • その他欧州
  • アジア太平洋の売上分析
    • 概要・実績・予測
    • アジア太平洋：セグメント別
    • アジア太平洋：国別
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • 東南アジア
    • その他アジア太平洋
  • ラテンアメリカの売上分析
    • 概要・実績・予測
    • ラテンアメリカ：セグメント別
    • ラテンアメリカ：国別
    • ブラジル
    • アルゼンチン
    • ペルー
    • チリ
    • その他ラテンアメリカ
  • 中東・アフリカの売上分析
    • 概要・実績・予測
    • 中東・アフリカ：セグメント別
    • 中東・アフリカ：国別
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他中東・アフリカ

第8章 泌尿生殖器治療薬企業の競合情勢

  • 泌尿生殖器治療薬市場の競合
  • 提携・協力・協定
  • 合併・買収
  • 新製品の上市
  • その他の開発

第9章 企業プロファイル

  • 上位企業の市場シェア分析
  • 市場集中度
  • Abbott
  • Bristol-Myers Squibb Co.
  • Novartis AG
  • Genentech Inc.
  • F. Hoffmann-La RocheLtd.
  • Ionis Pharmaceuticals Inc.
  • Eli Lilly And Company
  • Merck & Co. Inc.
  • Pfizer Inc.
  • AstraZeneca
  • GlaxoSmithKline
  • Teva Pharmaceutical Industries Ltd.
  • Bayer AG
  • Allergan
  • Antares Pharma
図表

LIST OF TABLES

  • Market Snapshot
  • Drivers: Impact Analysis
  • Restraints: Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • Analysis By Indication (USD MN)
  • Prostate Cancer Market Sales By Geography (USD MN)
  • Ovarian Cancer Market Sales By Geography (USD MN)
  • Bladder Cancer Market Sales By Geography (USD MN)
  • Cervical Cancer Market Sales By Geography (USD MN)
  • Renal Cancer Market Sales By Geography (USD MN)
  • Erectile Dysfunction Market Sales By Geography (USD MN)
  • Urinary Tract Infections Market Sales By Geography (USD MN)
  • Urinary Incontinence & Overactive Bladder Market Sales By Geography (USD MN)
  • Sexually Transmitted Diseases Market Sales By Geography (USD MN)
  • Interstitial Cystitis Market Sales By Geography (USD MN)
  • Haematuria Market Sales By Geography (USD MN)
  • Benign Prostatic Hyperplasia Market Sales By Geography (USD MN)
  • Analysis By Product (USD MN)
  • Urologicals Market Sales By Geography (USD MN)
  • Hormonal Therapy Market Sales By Geography (USD MN)
  • Gynecological Market Sales By Geography (USD MN)
  • Anti-Infectives Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Genitourinary Drugs Market Sales By Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United States Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate By Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Genitourinary Drugs Report
  • Market Research Process
  • Market Research Methodology
  • Global Genitourinary Drugs Market Size, By Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis By Indication
  • Market Attractiveness Analysis By Product
  • Market Attractiveness Analysis By Region
  • Value Chain Analysis
  • Global Market Analysis By Indication (USD MN)
  • Prostate Cancer Market Sales By Geography (USD MN)
  • Ovarian Cancer Market Sales By Geography (USD MN)
  • Bladder Cancer Market Sales By Geography (USD MN)
  • Cervical Cancer Market Sales By Geography (USD MN)
  • Renal Cancer Market Sales By Geography (USD MN)
  • Erectile Dysfunction Market Sales By Geography (USD MN)
  • Urinary Tract Infections Market Sales By Geography (USD MN)
  • Urinary Incontinence & Overactive Bladder Market Sales By Geography (USD MN)
  • Sexually Transmitted Diseases Market Sales By Geography (USD MN)
  • Interstitial Cystitis Market Sales By Geography (USD MN)
  • Haematuria Market Sales By Geography (USD MN)
  • Benign Prostatic Hyperplasia Market Sales By Geography (USD MN)
  • Global Market Analysis By Product (USD MN)
  • Urologicals Market Sales By Geography (USD MN)
  • Hormonal Therapy Market Sales By Geography (USD MN)
  • Gynecological Market Sales By Geography (USD MN)
  • Anti-Infectives Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.

目次
Product Code: VMR112115297

The global demand for Genitourinary Drugs Market is presumed to reach the market size of nearly USD 41.22 Billion by 2032 from USD 35.23 Billion in 2023 with a CAGR of 1.76% under the study period 2024-2032.

Genitourinary drugs are pharmaceutical agents designed to treat disorders & diseases affecting the urinary tract and reproductive organs. These drugs encompass various therapeutic categories, including antibiotics, antivirals, antifungals, hormones, and immunosuppressants. They are used to manage conditions such as urinary tract infections (UTIs), erectile dysfunction, benign prostatic hyperplasia (BPH), infertility, sexually transmitted infections (STIs), and various cancers of the genitourinary system. Based on the disease or disorder being treated, these drugs may target pathogens, modulate hormone levels, reduce inflammation, or inhibit cancer cell growth.

MARKET DYNAMICS

The genitourinary drugs market is driven by the increasing prevalence of genitourinary disorders, advancements in drug development, and evolving healthcare demographics. The rising incidence of genitourinary conditions such as UTIs, prostate disorders, and sexually transmitted diseases propels the demand for effective pharmaceutical treatments. Rapid urbanization, lifestyle changes, and aging populations contribute to a higher disease burden, necessitating continuous innovation in genitourinary drug therapies. Moreover, advancements in drug delivery systems, personalized medicine approaches, and biomarker identification enhance treatment efficacy and patient outcomes. Targeted therapies for conditions like prostate cancer and erectile dysfunction are expanding treatment options and improving the quality of life for affected individuals. Furthermore, growing healthcare expenditure and investments in urological research drive market expansion. Pharmaceutical companies focus on developing novel therapies & expanding indications for existing drugs to address unmet medical needs in genitourinary medicine. Increasing awareness about reproductive health, proactive screening initiatives, and patient education programs also foster genitourinary drugs market growth. Healthcare providers and policymakers prioritize preventive care and early intervention strategies, supporting market uptake of genitourinary drugs. However, stringent regulatory requirements for drug approval and patent expirations challenge market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Genitourinary Drugs. The growth and trends of Genitourinary Drugs industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Genitourinary Drugs market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Indication

  • Prostate Cancer
  • Ovarian Cancer
  • Bladder Cancer
  • Cervical Cancer
  • Renal Cancer
  • Erectile Dysfunction
  • Urinary Tract Infections
  • Urinary Incontinence & Overactive Bladder
  • Sexually Transmitted Diseases
  • Interstitial Cystitis
  • Haematuria
  • Benign Prostatic Hyperplasia

By Product

  • Urologicals
  • Hormonal Therapy
  • Gynecological
  • Anti-Infectives
  • Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Genitourinary Drugs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Genitourinary Drugs market include Abbott, Bristol-Myers Squibb Co., Novartis AG, Genentech Inc., F. Hoffmann-La RocheLtd., Ionis Pharmaceuticals Inc., Eli Lilly And Company, Merck & Co. Inc., Pfizer Inc., AstraZeneca, GlaxoSmithKline, Teva Pharmaceutical Industries Ltd., Bayer AG, Allergan, Antares Pharma. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. GENITOURINARY DRUGS - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Indication
    • 3.7.2 Market Attractiveness Analysis By Product
    • 3.7.3 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL GENITOURINARY DRUGS MARKET ANALYSIS BY INDICATION

  • 5.1. Overview By Indication
  • 5.2. Historical and Forecast Data Analysis By Indication
  • 5.3. Prostate Cancer Historic and Forecast Sales By Regions
  • 5.4. Ovarian Cancer Historic and Forecast Sales By Regions
  • 5.5. Bladder Cancer Historic and Forecast Sales By Regions
  • 5.6. Cervical Cancer Historic and Forecast Sales By Regions
  • 5.7. Renal Cancer Historic and Forecast Sales By Regions
  • 5.8. Erectile Dysfunction Historic and Forecast Sales By Regions
  • 5.9. Urinary Tract Infections Historic and Forecast Sales By Regions
  • 5.10. Urinary Incontinence & Overactive Bladder Historic and Forecast Sales By Regions
  • 5.11. Sexually Transmitted Diseases Historic and Forecast Sales By Regions
  • 5.12. Interstitial Cystitis Historic and Forecast Sales By Regions
  • 5.13. Haematuria Historic and Forecast Sales By Regions
  • 5.14. Benign Prostatic Hyperplasia Historic and Forecast Sales By Regions

6. GLOBAL GENITOURINARY DRUGS MARKET ANALYSIS BY PRODUCT

  • 6.1. Overview By Product
  • 6.2. Historical and Forecast Data Analysis By Product
  • 6.3. Urologicals Historic and Forecast Sales By Regions
  • 6.4. Hormonal Therapy Historic and Forecast Sales By Regions
  • 6.5. Gynecological Historic and Forecast Sales By Regions
  • 6.6. Anti-Infectives Historic and Forecast Sales By Regions
  • 6.7. Others Historic and Forecast Sales By Regions

7. GLOBAL GENITOURINARY DRUGS MARKET ANALYSIS BY GEOGRAPHY

  • 7.1. Regional Outlook
  • 7.2. Introduction
  • 7.3. North America Sales Analysis
    • 7.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 7.3.2 North America By Segment Sales Analysis
    • 7.3.3 North America By Country Sales Analysis
    • 7.3.4 United States Sales Analysis
    • 7.3.5 Canada Sales Analysis
    • 7.3.6 Mexico Sales Analysis
  • 7.4. Europe Sales Analysis
    • 7.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 7.4.2 Europe By Segment Sales Analysis
    • 7.4.3 Europe By Country Sales Analysis
    • 7.4.4 United Kingdom Sales Analysis
    • 7.4.5 France Sales Analysis
    • 7.4.6 Germany Sales Analysis
    • 7.4.7 Italy Sales Analysis
    • 7.4.8 Russia Sales Analysis
    • 7.4.9 Rest Of Europe Sales Analysis
  • 7.5. Asia Pacific Sales Analysis
    • 7.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 7.5.2 Asia Pacific By Segment Sales Analysis
    • 7.5.3 Asia Pacific By Country Sales Analysis
    • 7.5.4 China Sales Analysis
    • 7.5.5 India Sales Analysis
    • 7.5.6 Japan Sales Analysis
    • 7.5.7 South Korea Sales Analysis
    • 7.5.8 Australia Sales Analysis
    • 7.5.9 South East Asia Sales Analysis
    • 7.5.10 Rest Of Asia Pacific Sales Analysis
  • 7.6. Latin America Sales Analysis
    • 7.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 7.6.2 Latin America By Segment Sales Analysis
    • 7.6.3 Latin America By Country Sales Analysis
    • 7.6.4 Brazil Sales Analysis
    • 7.6.5 Argentina Sales Analysis
    • 7.6.6 Peru Sales Analysis
    • 7.6.7 Chile Sales Analysis
    • 7.6.8 Rest of Latin America Sales Analysis
  • 7.7. Middle East & Africa Sales Analysis
    • 7.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 7.7.2 Middle East & Africa By Segment Sales Analysis
    • 7.7.3 Middle East & Africa By Country Sales Analysis
    • 7.7.4 Saudi Arabia Sales Analysis
    • 7.7.5 UAE Sales Analysis
    • 7.7.6 Israel Sales Analysis
    • 7.7.7 South Africa Sales Analysis
    • 7.7.8 Rest Of Middle East And Africa Sales Analysis

8. COMPETITIVE LANDSCAPE OF THE GENITOURINARY DRUGS COMPANIES

  • 8.1. Genitourinary Drugs Market Competition
  • 8.2. Partnership/Collaboration/Agreement
  • 8.3. Merger And Acquisitions
  • 8.4. New Product Launch
  • 8.5. Other Developments

9. COMPANY PROFILES OF GENITOURINARY DRUGS INDUSTRY

  • 9.1. Top Companies Market Share Analysis
  • 9.2. Market Concentration Rate
  • 9.3. Abbott
    • 9.3.1 Company Overview
    • 9.3.2 Company Revenue
    • 9.3.3 Products
    • 9.3.4 Recent Developments
  • 9.4. Bristol-Myers Squibb Co.
    • 9.4.1 Company Overview
    • 9.4.2 Company Revenue
    • 9.4.3 Products
    • 9.4.4 Recent Developments
  • 9.5. Novartis AG
    • 9.5.1 Company Overview
    • 9.5.2 Company Revenue
    • 9.5.3 Products
    • 9.5.4 Recent Developments
  • 9.6. Genentech Inc.
    • 9.6.1 Company Overview
    • 9.6.2 Company Revenue
    • 9.6.3 Products
    • 9.6.4 Recent Developments
  • 9.7. F. Hoffmann-La RocheLtd.
    • 9.7.1 Company Overview
    • 9.7.2 Company Revenue
    • 9.7.3 Products
    • 9.7.4 Recent Developments
  • 9.8. Ionis Pharmaceuticals Inc.
    • 9.8.1 Company Overview
    • 9.8.2 Company Revenue
    • 9.8.3 Products
    • 9.8.4 Recent Developments
  • 9.9. Eli Lilly And Company
    • 9.9.1 Company Overview
    • 9.9.2 Company Revenue
    • 9.9.3 Products
    • 9.9.4 Recent Developments
  • 9.10. Merck & Co. Inc.
    • 9.10.1 Company Overview
    • 9.10.2 Company Revenue
    • 9.10.3 Products
    • 9.10.4 Recent Developments
  • 9.11. Pfizer Inc.
    • 9.11.1 Company Overview
    • 9.11.2 Company Revenue
    • 9.11.3 Products
    • 9.11.4 Recent Developments
  • 9.12. AstraZeneca
    • 9.12.1 Company Overview
    • 9.12.2 Company Revenue
    • 9.12.3 Products
    • 9.12.4 Recent Developments
  • 9.13. GlaxoSmithKline
    • 9.13.1 Company Overview
    • 9.13.2 Company Revenue
    • 9.13.3 Products
    • 9.13.4 Recent Developments
  • 9.14. Teva Pharmaceutical Industries Ltd.
    • 9.14.1 Company Overview
    • 9.14.2 Company Revenue
    • 9.14.3 Products
    • 9.14.4 Recent Developments
  • 9.15. Bayer AG
    • 9.15.1 Company Overview
    • 9.15.2 Company Revenue
    • 9.15.3 Products
    • 9.15.4 Recent Developments
  • 9.16. Allergan
    • 9.16.1 Company Overview
    • 9.16.2 Company Revenue
    • 9.16.3 Products
    • 9.16.4 Recent Developments
  • 9.17. Antares Pharma
    • 9.17.1 Company Overview
    • 9.17.2 Company Revenue
    • 9.17.3 Products
    • 9.17.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies